Exhibit 10.2 SEPARATION AGREEMENT AND MUTUAL RELEASE This Separation Agreement and Mutual Release (“Agreement”) is made by and between Ron Oyston (“Employee”) and ACELYRIN, INC. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed by the Company as Chief People Officer; WHEREAS, Employee signed a Proprietary Information and Inventions Assignment Agreement with the Company (the “Confidentiality Agreement”); WHEREAS, the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-K ________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to __________________ Commission file number ...

Exhibit 99.1 ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with high statistical significance in global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis with robust clinical responses also achieved for higher hurdle endpoints Announced differentiated long-term 32-week data from ...

Acelyrin Inc. (NASDAQ:SLRN) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations, Communications, Corporate Operations Shao-Lee Lin - Founder, Chief Executive Officer and Director Gil Labrucherie - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Analyst, Piper Sandler Emily Bodnar - Analyst, H.C. Wainwright and Company Akash Tewari - Analyst, Jefferies Tyler Van Buren - TD Cowen Vikram Purohit - Morgan St ...

ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights November 7, 2023 Portfolio of programs continues to advance with data from both the global Phase 2b/3 trial for izokibep in PsA and proof-of-concept for lonigutamab as a subcutaneous treatment for thyroid eye disease expected in first quarter 2024 Additional PsA Phase 2 long-term data on clinical measures of disease resolution and quality of life to be presented at 2023 Annual Meeting of the American College of Rheumatology Ca ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 001-41696 ACELYRIN, INC. (Exact name of registrant as specified in its charter) Delaware 85-24067 ...

财务数据和关键指标变化 - 公司在2023年5月成功完成首次公开发行,募集资金6.21亿美元 [42] - 截至2023年6月30日,公司现金及现金等价物和短期可变现证券总额为8.23亿美元,预计可为公司关键里程碑提供资金支持 [43] - 2023年第二季度研发费用为3000万美元,较2022年同期增加17.3百万美元,主要由于公司临床项目的扩展和新项目的增加 [43][44] - 2023年第二季度一般及行政费用为12.7百万美元,较2022年同期增加10.5百万美元,主要由于公司组织能力的扩大以支持广泛的免疫学产品候选物的开发和商业化 [45] - 2023年第二季度净亏损为2600万美元,较2022年同期增加11.5百万美元 [46] 各条业务线数据和关键指标变化 - 公司的主要项目是免疫学领域的izokibep、lonigutamab和SLRN-517 [8][32][38] - izokibep在银屑病性关节炎(PsA)和化脓性汗腺炎(HS)的临床试验数据显示了良好的疗效,包括关节、皮肤和腱膜炎症状的快速和持续改善 [25][26][27] - 公司正在推进izokibep在葡萄膜炎和轴性脊柱关节炎的III期临床试验 [28][29] - lonigutamab正在进行I/II期临床试验,评估其在甲状腺眼病的疗效和安全性 [32][33][35] - SLRN-517正在进行I/II期临床试验,评估其在慢性荨麻疹等肥大细胞驱动性疾病的疗效 [38][39][40] 各个市场数据和关键指标变化 - 公司的主要市场集中在免疫性疾病,包括化脓性汗腺炎、银屑病性关节炎、葡萄膜炎和轴性脊柱关节炎等 [16][24][28][29] - 化脓性汗腺炎在美国有超过30万名患者,其中一半为中重度 [16] - 银屑病性关节炎在美国有约160万名患者,其中约60%为中重度 [24] - 公司预计免疫性疾病治疗市场将从目前的10亿-20亿美元增长到2030年的40亿-50亿美元 [92][93] 公司战略和发展方向及行业竞争 - 公司致力于成为一家领先的可持续性生物制药公司,为多个大型全球市场提供临床上有差异化的新药物 [13] - 公司的核心价值观是"勇敢的关怀",致力于为患者带来生命改变的治疗方案 [8] - 公司正在积极推进izokibep、lonigutamab和SLRN-517在多个适应症的临床开发,预计未来两年内将有多个重要临床数据读出 [49] - 公司正在建立一支经验丰富的生物制药领导团队,以支持公司的发展战略 [11] - 公司面临来自其他IL-17抑制剂和IGF-1R抑制剂的竞争,但相信自身产品的高亲和力和小分子量可带来临床上的差异化优势 [15][33][39] 管理层对经营环境和未来前景的评论 - 公司对自身产品在多个适应症的临床试验结果表示乐观,认为高亲和力和小分子量可带来显著的临床获益 [15][27][48] - 公司认为,在化脓性汗腺炎和银屑病性关节炎等疾病中,实现疾病症状的快速和持续改善对于改善患者生活质量至关重要 [24][48] - 公司预计未来两年内将有多个重要临床数据读出,为公司带来重要的里程碑 [49] - 公司认为自身强大的财务实力和经验丰富的管理团队,为实现公司的发展愿景提供了坚实的基础 [12][42][46] 其他重要信息 - 公司于2023年5月完成首次公开发行,募集资金6.21亿美元 [42] - 公司任命Ken Lock为首席商务官,加强商业化能力 [11] - 公司原首席财务官Mardi Dier已离职,由Gil Labrucherie担任临时CFO [11][12] - 公司的临床项目进展超预期,多个关键试验的数据读出时间提前 [21][49] 问答环节重要的提问和回答 问题1 **Tyler Van Buren 提问** 对于新公布的化脓性汗腺炎患者中引流隧道改善的数据,公司如何将其与竞争对手MoonLake和UCB的数据进行比较?公司在即将公布的化脓性汗腺炎II/III期试验中,对HiSCR75的目标是什么? [54][55] **Shao-Lee Lin 回答** 公司认为,自身数据显示引流隧道在4周内即可出现改善,这可能是首次在该时间点观察到此类结果。公司的目标是达到至少与现有最佳疗效相当,甚至更好的HiSCR75反应率,预计在30%-35%左右。但公司的最终目标是追求能够带来临床上有意义差异化的治疗效果,包括HiSCR90和HiSCR100这样更高水平的疾病控制。 [79][80][81][82] 问题2 **Vikram Purohit 提问** 如果化脓性汗腺炎II/III期试验的结果呈现积极,对公司其他适应症如银屑病性关节炎的临床开发有何启示? [89] **Shao-Lee Lin 回答** 公司认为,无论是化脓性汗腺炎还是其他适应症,只要达到了临床上有意义的差异化疗效,且无额外安全性隐患,这将为公司的整体临床项目组合带来积极的信号。公司相信,izokibep的高亲和力和小分子量特性,有望在难治性组织如腱膜炎等方面展现出更好的疗效,这对于公司其他适应症的开

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 001-41696 ACELYRIN, INC. (Exact name of registrant as specified in its charter) Delaware 85-2406735 (S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 001-41696 ACELYRIN, INC. (Exact name of registrant as specified in its charter) Delaware 85-2406735 ( ...